INFERR-Iron Infusion in Haemodialysis Primary Data

End-stage kidney disease (ESKD) rates for Aboriginal and Torres Strait Islander people in remote areas are up to 30 times higher than the national average. Anaemia is a major complication of ESKD and often exacerbated by iron deficiency. It reduces quality of life and is associated with cardiovascular (CV) events and premature death. Erythropoietin (EPO) is the main agent used to correct anaemia but requires adequate iron stores to work effectively. Both EPO and IV iron are routine treatment for dialysis patients. Blood tests for ferritin and transferrin saturation are used to guide iron therapy. Ferritin is low with iron deficiency, but it is raised with ongoing inflammation or infection. Aboriginal and Torres Strait Islander dialysis patients have co-existing iron deficiency, high ferritin and ongoing inflammation. In this setting, there is no evidence to guide the use of IV iron and we do not understand the balance of benefits and harms of this routinely administered treatment. The primary outcome is a composite outcome measure with: 1. All-cause death 2. Hospitalisation with a principal diagnosis of all-cause infection Data Description • Hospitalisations • Pathology Results • Comorbidities/Medical History • Prescribed medications

偏远地区澳大利亚原住民和托雷斯海峡岛民的终末期肾病（End-stage kidney disease, ESKD）患病率可达全国平均水平的30倍。贫血是终末期肾病的主要并发症，常因铁缺乏而加重，可降低患者生活质量，并与心血管（CV）事件及过早死亡相关。促红细胞生成素（Erythropoietin, EPO）是纠正贫血的核心治疗药物，但需充足的铁储备方可发挥有效作用。促红细胞生成素与静脉铁剂（IV iron）均为透析患者的常规治疗方案。通过检测血清铁蛋白与转铁蛋白饱和度，可指导铁剂治疗的制定：铁缺乏时血清铁蛋白水平降低，但在持续炎症或感染状态下其水平会升高。澳大利亚原住民和托雷斯海峡岛民透析患者往往同时存在铁缺乏、血清铁蛋白升高及持续炎症的情况。在此临床场景下，尚无证据可指导静脉铁剂的合理使用，我们也尚未明确这一常规治疗手段的获益与风险平衡。本研究的主要结局为复合结局指标，包含以下两项：1. 全因死亡；2. 以全因感染为主要诊断的住院事件。数据集涵盖内容如下：• 住院情况 • 检验结果 • 合并症/病史 • 处方药物